Project Grant R43AI126979

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $256,000 will develop Recombinant BCG as a novel immunoadjuvant for viral infections. The awardee, Oncosting LLC located in Baltimore, Maryland, will optimize media and lyophilization manufacturing of BCG-STING, evaluate its immunological effects as an adjuvant for H1N1 influenza vaccination, and assess its protective effects as an H1N1 vaccine adjuvant. By adding stimulator of...

Viva Viral Vaccines, Inc. received a $299,968 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 25, 2025, through August 31, 2026. The project is being conducted in Ithaca, New York. The award funds development of a broad-spectrum, multivalent vaccine platform targeting influenza neuraminidase (NA) protein that addresses critical limitations in current...

Federal Cooperative Agreement Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Cooperative Agreement valued at $1.67 million under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a Phase 1 clinical study of a novel messenger ribonucleic acid (mRNA)-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The research, initiated September 25, 2025, and scheduled for completion by July...

Federal Project Grant Award Summary Antigen Discovery Inc. (ADI), doing business as Immport Therapeutics Inc., received a $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 12, 2025, with completion targeted for July 31, 2027. The award supports the development and optimization of novel cryptosporidium vaccine candidates through production of purified...

Federal Project Grant Award Summary L2 Diagnostics LLC received a $281,786 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded on September 23, 2025, with completion scheduled for August 31, 2027. The company will develop a viral vector-based vaccine against Powassan virus (POWV), a tick-borne pathogen in the Flavivirus family. The vaccine platform utilizes Modified Vaccinia Ankara...

This Project Grant award from the National Institute of Allergy and Infectious Diseases supports the development of a novel plant-based source for squalene as a natural vaccine adjuvant. The $514,006 award to Synshark LLC supports research to engineer tobacco plants to stably produce and accumulate squalene on their leaves. This work directly relates to the commercialization plan to provide a non-animal, indoor grown natural adjuvant for vaccines. Currently, squalene used in vaccines is...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $454,278 to The University of Kentucky Research Foundation on August 15, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project, entitled "Adjuvanted Intranasal Influenza Vaccine to Generate Lung Resident-Memory T Cells," will develop and evaluate a novel influenza vaccine formulation designed to provide broadly cross-reactive and...

Federal Grant Award Summary Via Therapeutics, LLC received a $314,363 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 11, 2025, through August 31, 2026. The company is developing a microneedle-based messenger RNA (mRNA) flu vaccine candidate designed for transcutaneous (intradermal) immunization. The project leverages Via Therapeutics' proprietary thin-film...

The federal Cooperative Agreement award U19AI181984, totaling $44,108,652.00, was granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of this 3-year award is to develop vaccines and antibody-based treatments for viruses in the Paramyxoviridae, Peribunyaviridae, and Phleboviridae families, with a focus on prototype viruses such as human parainfluenza virus 3 (HPIV3), Oropouche virus...

Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $458,250 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 4, 2025, with a completion date of August 31, 2027. The project, titled "A VP4-Based Pseudovirus Nanoparticle Rotavirus Vaccine for Oral Immunization," focuses on developing a non-replicating rotavirus...